Table 1 Impact of prognostic factors on... | American Society of Hematology

Table 1

Impact of prognostic factors on relapse-free survival and OS

Prognostic factor	Univariate analysis: P	Multivariate analysis: HR (95% CI), P
Relapse-free survival
HGs	.001	0.50 (0.28-0.90), < .03
Age	.18	0.99 (0.98-1.01), .72
Chemotherapy cycle*	< .0001	2.69 (1.19-6.06), < .02
Leukocytosis	< .0001	1.08 (1.02-1.15), < .007
Risk subgroup†	< .0001‡
Favorable		1 (referent)
Intermediate-I		3.55 (1.63-7.75), < .002
Intermediate-II		1.65 (0.73-3.72), .2
Adverse		5.28 (2.35-11.85), < .0001
OS
HGs	.011	0.62 (0.30-1.29), .2
Age	.22	1.00 (0.98-1.02), .9
Chemotherapy cycle*	.0072	2.65 (1.06-6.60), < .04
Leukocytosis	< .0001	1.13 (1.05-1.22), .0007
Risk subgroup†	< .02‡
Favorable		1 (referent)
Intermediate-I		2.46 (1.03-5.89), < .05
Intermediate-II		1.55 (0.62-3.86), .3
Adverse		3.51 (1.39-8.85), < .008

Prognostic factor	Univariate analysis: P	Multivariate analysis: HR (95% CI), P
Relapse-free survival
HGs	.001	0.50 (0.28-0.90), < .03
Age	.18	0.99 (0.98-1.01), .72
Chemotherapy cycle*	< .0001	2.69 (1.19-6.06), < .02
Leukocytosis	< .0001	1.08 (1.02-1.15), < .007
Risk subgroup†	< .0001‡
Favorable		1 (referent)
Intermediate-I		3.55 (1.63-7.75), < .002
Intermediate-II		1.65 (0.73-3.72), .2
Adverse		5.28 (2.35-11.85), < .0001
OS
HGs	.011	0.62 (0.30-1.29), .2
Age	.22	1.00 (0.98-1.02), .9
Chemotherapy cycle*	.0072	2.65 (1.06-6.60), < .04
Leukocytosis	< .0001	1.13 (1.05-1.22), .0007
Risk subgroup†	< .02‡
Favorable		1 (referent)
Intermediate-I		2.46 (1.03-5.89), < .05
Intermediate-II		1.55 (0.62-3.86), .3
Adverse		3.51 (1.39-8.85), < .008

Number of chemotherapy cycles required to achieve complete remission.

Dohner et al.¹²

According to overall log-rank test.